1. N-(7-chloro-n-quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide
1. Evp-6124
2. 550999-75-2
3. Evp 6124
4. Evp6124
5. N-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide
6. Chembl2151572
7. 5fi5376a0x
8. Mt4666
9. Mt-4666
10. Benzo(b)thiophene-2-carboxamide, N-(3r)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-
11. (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
12. 7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
13. Unii-5fi5376a0x
14. Encenicline [usan:inn]
15. Frm-6124
16. I33
17. Encenicline [inn]
18. Encenicline (usan/inn)
19. Encenicline [usan]
20. Encenicline [who-dd]
21. Schembl744767
22. Gtpl6926
23. (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide
24. Dtxsid701025836
25. Ex-a3984
26. Bdbm50393255
27. Mfcd23381267
28. Zinc95579362
29. Cs-0933
30. Db11726
31. Ncgc00378871-01
32. Hy-15430
33. D10626
34. A913801
35. Q19904062
36. (r)-7-chloro-n-(quinuclidine-3-yl)benzo[b]thiophene-2-carboxamide
37. N-((3r)-1-azabicyclo(2.2.2)oct-3-yl)-7-chloro-1-benzothiophene-2-carboxamide
38. N-(3r)-1-azabicyclo[2.2.2]oct-3-yl-7-chlorobenzo[b]thiophene-2-carboxamide
39. 1275596-71-8
| Molecular Weight | 320.8 g/mol |
|---|---|
| Molecular Formula | C16H17ClN2OS |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 320.0750120 g/mol |
| Monoisotopic Mass | 320.0750120 g/mol |
| Topological Polar Surface Area | 60.6 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 413 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Encenicline, a selective, orally active, alpha 7 Nicotinic Acetylcholine Receptor agonist (alpha 7 NAchR agonist). Encenicline may have a similar mechanism of action to GTS-21. Auditory sensory gating, a biological measurement of the ability to suppress the evoked response to the second of two auditory stimuli, is diminished in people with schizophrenia. Deficits in sensory gating are associated with attentional impairment, and may contribute to cognitive symptoms and perceptual disturbances. This inhibitory process, which involves the alpha(7) nicotinic receptor mediated release of gamma-aminobutyric acid (GABA) by hippocampal interneurons, represents a potential new target for therapeutic intervention in schizophrenia.
